Watch our video to learn more about the Xilis MOSTM platform and how it selects the optimal therapy choice for each individual patient.

Publication and Abstract Index Utilizing MOSTM Technology

Micro-Organospheres (MOSTM) retain patient tumor microenvironment for precision immuno-oncology

Read More

Patient-derived micro-organospheres enable clinical precision oncology

Read More

A Micro-organosphere Potency Assay for Adoptive T Cell Therapy

Read More

Patient-derived micro-organospheres (MOSTM) recapitulate tumor microenvironment and heterogeneity for precision oncology.

Read More

Other Cancers

As the second most common cause of death in the United States, cancer has placed a significant socioeconomic burden on the healthcare system. There is an estimated 1.9 million new cases of cancer and over 600,000 deaths linked to cancer.1 Xilis is developing its MicroOrganoSphereTM platform, which recapitulates the tumor microenvironment and cancer heterogeneity, for precision oncology and the evaluation of chemotherapy and immunotherapy research applications.

American Cancer Society:
Accessed September 2021.